|
Change in outcome parameters after 4 weeks of treatment*. |
|||||
| Treatment groups |
|||||
|
|
|||||
| Parameter |
Placebo (n = 45) |
Diclofenac (n = 49) |
EA (n = 46) |
Combined (n = 46) |
p-valuea |
|
|
|||||
| Number of paracetamol taken (tablets taken per week) |
-5.16 (2.33) |
-4.43 (1.90) |
-7.89 (2.09) |
-5.13 (2.06) |
NS |
| 50 feet-walk time (sec) |
-2.70 (0.52) |
-3.52 (0.46) |
-4.41 (0.70) |
-4.13 (0.54) |
NS |
| VAS |
-22.86 (4.02) |
-32.99 (3.94) |
-48.24 (3.59) |
-35.59 (2.74) |
<0.05† |
| WOMAC |
|||||
| Pain index |
-3.31 (0.68) |
-4.90 (0.53) |
-5.65 (0.59) |
-6.28 (0.77) |
<0.05†† |
| Stiffness index |
-1.47 (0.31) |
-1.55 (0.27) |
-2.24 (0.31) |
-2.02 (0.28) |
NS |
| Disability index |
-12.33 (1.88) |
-14.39 (1.77) |
-19.17 (2.05) |
-18.98 (1.92) |
NS |
| Total score |
-17.11 (2.73) |
-20.84 (2.43) |
-27.07 (2.78) |
-27.28 (2.79) |
NS |
| Lequesne's functional index |
-3.82 (0.51) |
-4.80 (0.61) |
-6.44 (0.59) |
-5.39 (0.52) |
<0.05††† |
|
*Compared values of week 4 versus those of week 0 (run-in peroid), data represent mean (SEM). Statistic analysis: a = one-way ANOVA and Scheffe method. NS= no statistical significance. † = EA vs placebo and diclofenac group. †† = combined vs placebo group. ††† = EA vs placebo group. | |||||
Sangdee et al. BMC Complementary and Alternative Medicine 2002 2:3 doi:10.1186/1472-6882-2-3 |
|||||